Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Posted on
by

This article by Dr. Prashanth Rawla, et al., is published in the Journal of Inflammation Research, Volume 11, 2018: 215-226.

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal system that includes: ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available in the management of IBD.

Dr. Rawla’s research study has helped people better understand IBD and potential treatment options that help to alleviate symptoms and discomfort. His study has been widely read amongst the IBD community and offers much promise to better understanding the disease and treatment options for millions of people suffering from IBD worldwide. In his research piece, Dr. Rawla identifies trends in IBD diagnosis, treatment developments, the benefits of biologics, shifting treatment trends, and the future of novel agents and biosimilars that will likely be found in effective treatment solutions.

In his concluding remarks, Dr. Rawla finds that as the burden of IBD is increasing so is the plethora of novel agents under development for its treatment. Initially, biologics were prescribed much later in the course of the disease, but this paradigm has changed with the increasing availability of evidence that suggests early use of biological agents. One of the significant hurdles faced currently with these newer biologics is the cost and adverse reactions, but the availability of biosimilars in the market now, the cost has come down drastically. In the future with novel agents in the pipeline, one could expect to see agents with enhanced safety and tolerability.

Access the article here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961645

Other research studies done by Dr. Rawla of interest include:

Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277325/

Fecal microbiota transplant – a new frontier in inflammatory bowel disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124474/

Review of infectious etiology of acute pancreatitis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505279/

Media Contact
Contact Person: Dr. Prashanth Rawla
Email: rred281@gmail.com
Phone: (732) 982-7357
Country: United States
Website: www.ncbi.nlm.nih.gov/pubmed?term=Rawla%2C%20Prashanth%5BAuthor%5D